1. Market Research
  2. > Therapy Market Trends
  3. > Cardiovascular Drug Industry
  4. > Cardiovascular Drug Industry Statistics

Cardiovascular Drug Industry Statistics

You might be interested in: Cardiovascular Disease, Pharmaceutical, Diabetes, Cardiology, Healthcare, Therapy, Anti-Infective, Statins, Antidiabetics, Chemotherapy, Analgesic, Anti Rheumatic, Hormone, Opioid, Salicylic Acid, Targeted Therapy, Insulin, Lipid Modifying Drug, Anesthetics, Antidepressant.

1-7 of about 100 reports for Cardiovascular Drug

Download Unlimited Documents from Trusted Public Sources

Global Cardiovascular Drug Market

  • October 2015
    25 pages
  • Cardiovascular ...  

    Blood Disease  

    Cardiovascular ...  

  • World  

View report >

Cardiovascular Drug Market in the US

  • April 2016
    8 pages
  • Cardiovascular ...  

  • United States  

View report >

Cardiovascular Drug Market in Europe

  • January 2015
    113 pages
  • Cardiovascular ...  

    Blood Supply  

  • Europe  

View report >

Cardiovascular Drug Market in China

  • January 2015
    10 pages
  • Cardiovascular ...  

    Hypertension  

  • China  

View report >

Therapy and Cardiovascular Drug Market in the UK

  • March 2016
    82 pages
  • Therapy  

    Cardiovascular ...  

    Heart Failure  

  • United Kingdom  

View report >

Cardiovascular Drug Market in India

  • April 2016
    8 pages
  • Cardiovascular ...  

  • India  

View report >

Cardiovascular Drug and Therapy Market in Canada

  • January 2016
    6 pages
  • Cardiovascular ...  

    Therapy  

  • Canada  

View report >
10 reports for Cardiovascular Drug

Purchase Reports From Reputable Market Research Publishers
(From $ 595 - $ 4 000)

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

  • $ 754
  • Industry report
  • Jun 2016
  • by Firstword Pharma

The potential blockbuster status of Novartis' LCZ696 has seemingly been cemented in the eyes of the Street thanks to solid results from the Phase III PARADIGM-HF study that were presented over the weekend. ...


ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.